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The authors describe one case of a rare primitive non-Hodgkin lymphoma of the uterus, and two cases of primary non-Hodgkin lymphoma 
of the breast. Histologically, the uterine lymphoma, although clinically confined to the uterus, was a diffuse large cell lymphoma, group 
G according to the Working formulation for Clinical Usage. The two cases of breast lymphoma were a centrocytic-centroblastic and a 
lymphoplasmocytoid non-Hodgkin lymphoma, respectively. All cases were initally treated with radical surgery plus radiotherapy, but the 
first patient showed an early recurrence at distant sites, which required systemic eytotoxic hemotherapy. The patient with uterine non- 
Hodgkin iymphoma received a very intense regimen--i.e, the ProMACE-Cytabonv---because of the unfavourable histology, while the two 
patients with primary breast non-Hodgkin lymphoma received less aggressive CHOP and CVP chemotherapy. All patients are still alive 
and free of disease 3 to 6 years after initial diagnosis. These cases tress the systemic nature of non-Hodgkin lymphomas even if apparently 
localized to a single extranodal organ. Thus, although a definitive therapeutic strategy cannot be drawn from the rare and occasional 
reports in the medical literature, primary extranodal ymphomas require integrated multimodality therapy with radiotherapy and/or 
chemotherapy. 
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Introduction 
Non-Hodgkin lymphomas represent approximately 3% of all 
malignances in the United States which account for about 13,000 
deaths/year, j'2 Although in the medical iterature data concerning 
primary extranodal non-Hodgkin lymphomas (NHL) are rare and 
not unifocal, the diagnosis of a primary extranodal NHL is a rela- 
tively frequent occurrence in clinical ontology. In fact, up to one 
third of NHL may have an extranodal origin, expecially in the 
gastrointestinal nd the naso-oropharyngeal regions. However, 
extranodgl NHL may originate not only in organs containing well 
recognized lymphoid tissue such as small bowel Peyer's patches or 
tonsils, but also in individual organs that usually do not contain 
lymphoid tissue) '4in this paper we report one case of a primary 
NHL of the uterus and two cases of primary NHL of the breast. 
Both localizations, in particular the uterine one, are extremely rare 
forms of extranodal NHL. In fact, in a large review of 1467 extra- 
nodal NHL collected over 14 years at the National Cancer Institute 
of Bethesda, Maryland, USA, primary NHL of the uterus and the 
breast represented 0.002°/, and the 2.2% respectively, of the whole 
series/ Moreover, NHL represent only 0.1-0.5% of all breast 
tumours? 
Case 1: Primary NHL of the corpus uteri 
In June 1992 a 46-year-old white female was admitted at the Division 
of Gynecology of an affiliated Hospital in the city of Palermo for 
an unexplained persistent uterine haemorrhage. History was nega- 
tive for infections, neoplastic disorders, and immunodeficiency dis- 
eases. Physical examination failed to reveal any sign of disease, 
except for the uterine involvement. Gynaecological examination 
failed to detect significant abnormalities. No B symptoms were 
present, and all routine haematological and serum chemistry tests 
were normal except for a mild normocromic normocytic anaemia 
and a moderately increased ESR (54 mm/h). A hysteroscopy showed 
an area of hypertrophic abnormal mucosa localized in the fundus 
uteri which was biopsied. Histological analysis howed the presence 
*Ccorrespondence to: Mario Adelfio Latteri, Head Division of 
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of a uterine neoplasm represented by undifferentiated large cells 
with a sarcomatous appearance, which prompted the pathologist to 
put forward a tentative diagnosis of uterine sarcoma. Thus, the 
patient underwent total laparohysterectomy with bilateral oopho- 
rectomy without any significant post-surgical complication. Defini- 
tive histological analysis of the specimen surprisingly revealed the 
presence of a diffuse large cell NHL, group G, according to the 
Working Formulation of NHL for Clinical Usage/The neoplastic 
infiltration was confined to the corpus uteri, while the ovaries were 
normal. 
The patient was then referred to our Institution where she sought 
oncological advice at the end of August 1992. Extensive staging 
with physical examination, chest X-ray, abdominal sonogram, ORL 
examination, bilateral bone marrow biopsy, total body CT scan, 
abdomino-pelvic NMR, and routine haematological and chemistry 
tests, failed to detect any sign of disease. Tumour markers, including 
beta 2-microglobulin, were negative. Thus, a diagnosis of primary 
uterine NHL was eventually carried out. 
The patient was informed of the rarity of her disease, and was 
rapidly submitted for radiotherapy to the surgical field and loco- 
regional lymph node areas. Radiotherapy was given with an inverted 
Y field for a final dose of 45 gray (2 Gy/day x 5/week) from Sep- 
tember to the end of November 1992. Mild nausea was the only 
complaint during radiotherapy. Soon after completion of radio- 
therapy, clinical examination revealed the presence of four mobile, 
painless, small (1-2 cm) lymph nodes in the anterior area of the left 
axilla, one of which was surgically removed. A total body CT scan 
did not show any other enlarged or suspect lymph nodes elsewhere. 
Pathological nalysis again discovered the presence of a NHL with 
the same characteristics a the uterine one. Thus, the patient was 
given eight full,cycles of chemotherapy according to the ProMACE- 
MOPP regimen. 6 Recombinant granulocyte colony stimulating fac- 
tor 5 #g/kg/day was employed subcutaneously as necessary to pre- 
vent severe leukopenia enabling planned dose-intensity. During 
chemotherapy the patient complained of mild mucositis and com- 
plete transient alopecia, but vomiting was virtually absent due to 
the use of i.v. ondansetron. After completion of chemotherapy the 
patient was clinically and radiologically restaged also with total 
body CT scan without evidence of disease. Thus a complete response 
according to the WHO criteria was obtained/The patient is still 
alive and free of disease, 30 months from surgery 
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Primary NHL of the breast 
Case no. I 
In September 1987 a 47-year-old white female was admitted to 
our Institution for mastalgia. History was negative for infectious, 
neoplastic, lymphoproliferative, and immunodeficiency disease. 
Physical examination revealed the presence of a small (1 cm) painless 
mass in the upper outer quadrant of the right breast with a negative 
axilla. The breast lesion was smooth, mobile, and well defined. No 
suspicious lymphnodes were found elsewhere. Clinically, liver and 
spleen were not enlarged. No B symptoms were present. The results 
of routine laboratory tests revealed an increased ESR (62 mm/h), a 
mild hypocromic anaemia (Hb 11.2 g%), and a relatively low serum 
iron (40/~g%). Breast sonogram confirmed the presence of the solid 
nodule surrounded by a small group of calcifications, but aspiration 
of the mass was not diagnostic. An open biopsy was then performed, 
the nodule completely removed, and histological nalysis discovered 
the presence of a malignant centrocytic-centroblastic NHL accord- 
ing to the Kiel classification. ~ The margins of the surgical specimen 
were histologically free of turnout. 
The patients was then thoroughly staged with chest X-ray, 
abdominal sonogram, 99Tc bone scan, CT scan of the head/neck, 
thorax and the abdomen, and bilateral bone marrow biopsy with a 
Jamshidi needle. Routine haematological tests and serum chemistry 
were normal. All the above-mentioned examinations failed to dis- 
cover any sign of lymphomatous infiltration, and the disease was 
thus considered a primary NHL of the breast, stage IE according 
to the Ann Arbor staging system) 
The patient was subsequently given radiotherapy with a mantle 
field for a total of 45 gray (2 Gy/day x 5/week), and then closely 
followed-up. Forty-six months after surgery a nodal recurrence in 
the right axilla, inside the previous radiotherapy field, was found. 
The patient then underwent systemic hemotherapy with cyclo- 
phosphamide, vincristine, adriamycin and prednisone (CHOP regi- 
men). The major side-effects were alopecia nd granulocytopenia, 
but both were transient. After a total of eight cycles the patient was 
extensively restaged and a complete response according to the WHO 
criteria was found. 7 The patient is still alive without signs of disease 
after 6 years from diagnosis. 
Case no. 2 
In January 1990 a 54-year-old white female was seen at our breast 
screening outpatient clinic for a painless mass in the lower outer 
quadrant of the left breast. Medical history was negative for neo- 
plastic disorders and, in particular, for lymphoproliferative diseases. 
Clinical examination discovered a 3 x 3.5 cm smooth and mobile 
mass in the left breast. Non-palpable ymph nodes were found. Mam- 
mography showed a nearly round opacity with well-defined margins 
and without calcifications, which was aspirated for cytological 
analysis. Cytologic analysis revealed the presence of rare epithelial 
cells with hyperchromic and hypertrophic nuclei mixed with several 
lymphocytes. An open surgical biopsy of the lesion was then per- 
formed, and definitive histological analysis revealed the presence 
ofa lymphoplasmocytoid non-Hodgkin lymphoma (k chain) accord- 
ing to the Kiel classification s. Thus, no further surgery was carried 
out, and the patient was staged as described above for Case I. 
The disease was.considered a primary NHL of the breast stage I E. 
The patient was then given mantle field radiotherapy for a total 
final dose of 47 gray, plus systemic hemotherapy with the CVP 
regimen (cyclophosphamide, vincristine and prednisone) for eight 
cycles. Adriamycin was not included in the chemotherapy regimen 
due to the lymphoplasmocytoid type of NHL which is considered a 
low malignant lymphoma. After completion of radiotherapy and 
systemic hemotherapy, restaging did not reveal any sign of disease. 
To date the patient is still alive in good clinical conditions without 
any sign or symptom of disease after a follow up of 46 months. 
Discussion 
Organs containing well-recognized areas of lymphoid tissue, such 
as the stomach, tonsils, small bowel and skin, are by far the most 
common sites of origin of primary extranodal non-hodgkin lym- 
phomas 3"4. However, a primary extranodal NHL may occasionally 
occur in many other tissues which usually do not contain well 
identifiable lymphoid areas 4
Primary extranodal uterine NHL is an extremely rare form of 
malignant lymphoproliferative n oplastic disease of the uterus. In 
the absence of distant nodal metastases no particular symptoms are 
characteristic of such disease, and clinically it is not distinguishable 
from other more common malignancies of the uterus. In the case 
reported above, surgery was performed ue to the initial diagnosis 
of uterine sarcoma, but in view of the lympliomatous nature of the 
disease surgery plays more of a diagnostic role than a therapeutic 
one even if removal of the bulky uterine neoplasm retains its clinical 
importance for debulking. In fact, primary extranodal NHL, even 
if localized at diagnosis, tends to behave as a systemic disease as 
confirmed by the reported patient who showed early distant recur- 
rence after radical surgery and radiotherapy. 
Primary extranodal NHL of the breast is also a very rare neo- 
plastic disorder, representing 0.5% of all neoplastic diseases of the 
breast, and only 2.2% of all forms of primary extranodal NHL 9-H. 
Its clinical recognition isparticularly difficult as there are no clinical 
or radiological signs peculiar to this disease. The mean age of pat- 
ients with breast NHL varies from 45 to 65 years in different series, 
but generally the incidence seems to increase with age. This age 
range is not characteristic of NHL since it overlaps with the peak 
of incidence of breast carcinoma. However, other authors have 
reported the age pattern of incidence as a bimodal distribution: a 
younger group of patients with age mode of 33 years and a second 
older group with an age mode of 63 years ~. Few authors reported 
a prevalence ofprimary NHL in the right breast. The predominance 
is statistically significant compared to the left breast in which breast 
carcinoma is more frequent. Although some authors reported that 
histopathological type and clinical staging play a significant prog- 
nostic role ~°'L~, other authors failed to find such an association N. 
The role of surgery in primary breast NHL is mainly diagnostic 
since the lymphoproliferative disorder is a widespread disease often 
requiring systemic therapy. In fact, even if local control could be 
effectively achieved with radiotherapy alone, distant spread of the 
disease remains a major clinical problem since most patients will 
sooner or later develop distant recurrence despite optimal Ioco- 
regional therapy ~2.~s. However, Abbes et al concluded that exclusive 
radiation therapy could be justified in low-malignacy NHL, and 
systemic hemotherapy represented the mainstay of therapy for 
intermediate- and high-malignacy forms ~a. In this paper we report 
two cases of primary breast NHL: the first patient had an inter- 
mediate malignancy NHL, showed an early relapse after loco- 
regional treatment and thus received systemic hemotherapy which 
was successful in controlling the disease; the second patient had a 
low grade malignancy NHL, was treated with non-aggressive sys- 
temic chemotherapy before any relapse appeared. Survival of both 
cases is in the range reported by other authors. 9'm'a~ 
In conclusion, primary extranodal NHL of the uterus and the 
breast are very rare neoplastic disorders, for which diagnosis i  only 
obtained after a definitive histological and immunocytochemical 
analysis. The role of surgery, beside removing the primary mass, is 
mainly diagnostic since in most cases an extranodal NHL should be 
considered as a systemic disorder even when the disease seems well 
localized. Although a definitive therapeutic strategy cannot be 
drawn from the occasional reports in the medical iterature, of 
extranodal NHL arising in non-lymphoid organs, primary extra- 
nodal NHL, expecially intermediate- and high-malignancy forms, 
in our opinion, require integrated multimodality herapy with adju- 
vant radiotherapy and systemic chemotherapy, particularly, inthose 
cases with poor prognostic factors. 
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